ImmunityBio Revenue and Competitors
Estimated Revenue & Valuation
- ImmunityBio's estimated annual revenue is currently $1.5M per year.
- ImmunityBio's estimated revenue per employee is $2,275
- ImmunityBio's current valuation is $2.7B. (January 2022)
Employee Data
- ImmunityBio has 655 Employees.
- ImmunityBio grew their employee count by -6% last year.
ImmunityBio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is ImmunityBio?
Leading late-stage immunotherapy company harnessing immunogenic cell death by orchestrating both the innate (NK) and adaptive (T Cell) immune system through first-in-class immunological platforms. ImmunityBio (formerly NantCell) develops novel combinations of chemo-immune sensitizers, cell therapies, cytokines, vaccines, neoepitopes, and monoclonal antibody immunotherapies to orchestrate the NK and T Cell response for cancer and infectious diseases.
keywords:N/A
N/A
Total Funding
655
Number of Employees
$1.5M
Revenue (est)
-6%
Employee Growth %
$2.7B
Valuation
N/A
Accelerator
ImmunityBio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Technology Officer | Reveal Email/Phone |
2 | Project Manager | Reveal Email/Phone |
3 | VP Biometrics | Reveal Email/Phone |
4 | Manager, Regulatory Affairs | Reveal Email/Phone |
5 | Senior Investor Relations & Business Development Director | Reveal Email/Phone |
6 | Senior Clinical DB Programmer | Reveal Email/Phone |
7 | Director Manufacturing | Reveal Email/Phone |
8 | Area Business Director | Reveal Email/Phone |
9 | Sr. Manager Facilities | Reveal Email/Phone |
10 | Director, QC Analytical | Reveal Email/Phone |
ImmunityBio News
Data from ImmunityBio's QUILT 3.032 BCG-unresponsive non-muscle invasive bladder cancer trial will be presented by principal investigator in...
ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung...
ImmunityBio is a clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune...
Other Companies in Culver City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $265M | 701 | 3% | N/A |
#2 | $236.4M | 725 | 29% | $399M |
#3 | $304.3M | 805 | 10% | N/A |
#4 | $15M | 822 | 10% | N/A |
#5 | $298.5M | 935 | 18% | N/A |